$CYTR Recent Headlines Micron Tech shares fall after

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$CYTR Recent Headlines

Micron Tech shares fall after revenue miss 4:57 p.m. Jan. 6, 2015 - Wallace Witkowski
Six stocks to watch 2:29 p.m. Jan. 22, 2014 - The Trading Deck
CytRx's stock spike proves to be no fluke with another 20% share gain 11:39 a.m. Dec. 12, 2013 - Russ Britt
MasterCard, Visa among top S&P gainers; Avon in red 4:27 p.m. Dec. 11, 2013 - Sue Chang
Cancer drug test results send CytRx shares soaring by 75% 10:48 a.m. Dec. 11, 2013 - Russ Britt
CytRx jumps on results of aldoxorubicin trial 9:47 a.m. Dec. 11, 2013 - MarketWatch.com
Yum shares drop on outlook, soft China sales 5:10 p.m. Oct. 8, 2013 - Wallace Witkowski
Six companies unveil share, unit offerings 7:45 a.m. Dec. 7, 2012 - MarketWatch.com
Insider filings one way to track tricky micro-cap biotechs 11:14 a.m. Oct. 24, 2012 - blogs.marketwatch.com
CytRx prices offering at 20% discount 10:07 a.m. Oct. 18, 2012 - MarketWatch.com
CytRx down 20.6% in premarket 7:59 a.m. Oct. 18, 2012 - Steve Gelsi
CytRx rallies 27% on drug study update 11:49 a.m. July 25, 2012 - Val Brickates Kennedy
CytRx falls 12% in morning trading 10:02 a.m. June 4, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 3:40 p.m. April 28, 2011 - Kate Gibson
Dyax, Santarus, CytRx soar; Hemispherx craters 11:38 a.m. Dec. 2, 2009 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 5:00 p.m. June 30, 2009 - MarketWatch
Drug stocks retract; Vical, Geron, Novavax soar 1:29 p.m. June 30, 2009 - Val Brickates Kennedy
CytRx files FDA report on halted clinical trial 8:16 a.m. June 30, 2009 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 4:39 p.m. Jan. 22, 2008 - MarketWatch
Drug stocks tumble on U.S. economy jitters; CytRx slumps 1:33 p.m. Jan. 22, 2008 - Val Brickates Kennedy


CytRx up on interim trial results for KS in HIV patients 9:50 a.m. Jan. 8, 2015 - Seeking Alpha
CytRx Jumps on Positive Results from Brain Cancer Study - Analyst Blog 2:16 p.m. Jan. 7, 2015 - Zacks.com
4 Biotechnology Stocks to Sell Now 1:30 a.m. Jan. 7, 2015 - InvestorPlace.com
CytRx up on brain cancer trial results 9:03 a.m. Jan. 6, 2015 - Seeking Alpha
CytRx Reports Positive Results for Brain Cancer Treatment 8:02 a.m. Jan. 6, 2015 - The Wall Street Journal Interactive Edition
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ... 11:49 a.m. Dec. 15, 2014 - TheStreet.com
CytRx Falls on Written FDA Notice for Aldoxorubicin Study - Analyst Blog 5:20 p.m. Dec. 4, 2014 - Zacks.com
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off 11:00 a.m. Dec. 2, 2014 - TheStreet.com
CytRx Falls on Partial Study Hold on Oncology Candidate - Analyst Blog 5:21 p.m. Nov. 19, 2014 - Zacks.com
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog 11:23 a.m. Nov. 19, 2014 - Zacks.com
CytRx off premarket in response to FDA hold on aldoxorubicin trials 8:53 a.m. Nov. 18, 2014 - Seeking Alpha
More Fallout From Stock Promotion Scandal 2:35 p.m. Nov. 14, 2014 - Seeking Alpha
10-Q: CYTRX CORP 6:05 a.m. Nov. 4, 2014 - Edgar Online - (EDG = 10Q, 10K)
5 Red-Hot Biotech Stocks to Buy 4:33 a.m. Oct. 27, 2014 - InvestorPlace.com
Three Lessons From The Galena Scandal 10:02 a.m. Aug. 21, 2014 - Seeking Alpha
RXi Pharmaceuticals: Early-Stage Biotech With A Promising Future 4:22 p.m. Aug. 4, 2014 - Seeking Alpha
Biotech Accused in Stock-Pump Scheme 10:11 a.m. July 8, 2014 - Barrons.com
Five Analyst Stock Picks With 100% or More Implied Upside 7:31 a.m. June 7, 2014 - 247WallSt.com
Celldex: The Race Leader In Glioblastoma Multiforme 2:17 p.m. May 29, 2014 - Seeking Alpha
Aldoxorubicin increases PFS 6:53 a.m. May 28, 2014 - Seeking Alpha


Driving the Market: Special Research on Twitter, Frontline, CytRx, Tonix and American Electric 8:40 a.m. Jan. 7, 2015 - PR Newswire - PRF
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer) 6:00 a.m. Jan. 6, 2015 - PR Newswire - PRF
CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials 6:00 a.m. Dec. 3, 2014 - PR Newswire - PRF
CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference 6:00 a.m. Dec. 2, 2014 - PR Newswire - PRF
CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials 6:00 a.m. Nov. 18, 2014 - PR Newswire - PRF
CytRx Reports 2014 Third Quarter Financial Results 6:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 5:00 a.m. Oct. 30, 2014 - PR Newswire - PRF
CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia 5:00 a.m. Oct. 29, 2014 - PR Newswire - PRF
Big Board Biotech Stocks in Play This Week 1:17 p.m. Oct. 28, 2014 - ACCESSWIRE
Big Board Biotech Stocks in Play This Week 10:22 a.m. Oct. 28, 2014 - ACCESSWIRE
Big Board Biotech Stocks in Play This Week 10:22 a.m. Oct. 28, 2014 - ACCESSWIRE
Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 8:00 a.m. Oct. 24, 2014 - PR Newswire - PRF
CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society 5:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5:00 a.m. Oct. 17, 2014 - PR Newswire - PRF
CytRx Appoints Steven A. Kriegsman as Chairman of the Board 5:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform 5:00 a.m. Oct. 13, 2014 - PR Newswire - PRF
CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Gemcitabine in Patients with Metastatic Solid Tumors 5:00 a.m. Oct. 9, 2014 - PR Newswire - PRF
CytRx Announces Unexpected Passing of Chairman Max Link, PhD 3:05 p.m. Oct. 7, 2014 - PR Newswire - PRF
CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5:00 a.m. Sept. 29, 2014 - PR Newswire - PRF

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 92

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 158

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading

Top 5 Most Recently Viewed Articles

Jeff McLean Takes the Helm as ghSMART's New CEO

Updated Category News Views 620

Jeff McLean Takes the Helm as ghSMART's New CEO G.H. Smart & Company, LLC, the leading firm in leadership advisory, proudly announces the appointment of Jeff McLean as the Chief Executive Officer. McLean, who has been serving as President of ghSMART for three years, will now guide the firm towards its next exciting phase of growth and innovation. Achievements Under...

Continue Reading
Growth Forecast for Hot Dog and Sausage Market to 2032

Updated Category News Views 51

Introduction to the Hot Dog and Sausage Market The global market for hot dogs and sausages is witnessing a remarkable upward trajectory, with projections estimating it will reach USD 112.41 billion by 2032. This growth is fueled by a compound annual growth rate (CAGR) of 3.50%. The factors contributing to this expansion are numerous, including shifting consumer...

Continue Reading
Exro Technologies Adjusts Leadership with New CEO Plans

Updated Category News Views 337

Exro Technologies Announces Leadership Changes Exro Technologies Inc. has made a significant announcement regarding its leadership structure. Following the resignation of Sue Ozdemir from her role as Chief Executive Officer, the company has initiated steps to ensure a seamless transition and continuity in leadership. New Chief Restructuring Officer Appointed Introduction...

Continue Reading
Hillenbrand Increases Quarterly Dividend to $0.225 Per Share

Updated Category News Views 208

Hillenbrand's Exciting Dividend Announcement The board of directors of Hillenbrand, Inc. (NYSE: HI) has proudly announced a regular cash dividend of $0.225 per share on its common stock. This announcement signifies an annual increase of $0.01, bringing the total dividend rate to $0.90 per share for fiscal 2025. Such a commitment underlines Hillenbrand's dedication to...

Continue Reading
Trump's World Liberty Financial Token Sale Raises $220 Million

Updated Category News Views 113

Trump's World Liberty Financial Token Sale Demonstrates Huge Demand The World Liberty Financial project, closely associated with Donald Trump, made headlines recently as its token sale reached an impressive $220 million in just the first hour. Despite facing multiple outages on its website, the initiative showcased remarkable demand and interest. Details of the Token Sale...

Continue Reading